LY3023414 + midazolam

**LY3023414 + midazolam** is a **pharmaceutical combination** consisting of LY3023414 and midazolam. - **LY3023414** is a potent, selective, oral *ATP-competitive inhibitor* of *class I phosphoinositide 3-kinase (PI3K) isoforms*, *mTOR* (mammalian target of rapamycin), and *DNA-dependent protein kinase (DNA-PK)*. It is under development for advanced and treatment-refractory solid tumors and is being investigated for synergistic effects, particularly in endometrial and other cancers[2][3][1][6]. - **Midazolam** is a short-acting benzodiazepine used as a sedative, anxiolytic, and anesthetic adjunct, acting as a *positive allosteric modulator* of the *gamma-aminobutyric acid type A receptor (GABA-A receptor)*. There is no clinical or preclinical evidence of these two drugs being developed or marketed as a fixed combination. If referenced together, it may be in the context of pharmacokinetic interaction studies or specific research settings for drug-drug interaction (not combination treatment efficacy).